Product image of Montelukast 6 Hónap És 5 Év Közötti Gyermekek Számára Teva (Montelukast Sodium) supplied by GNH India

Montelukast 6 Hónap És 5 Év Közötti Gyermekek Számára Teva

Active Ingredient:
Montelukast Sodium
Origin:
EU

Montelukast 6 Hónap És 5 Év Közötti Gyermekek Számára Teva (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast 6 Hónap És 5 Év Közötti Gyermekek Számára Teva, is a leukotriene receptor antagonist presented as an oral formulation for use in children aged 6 months to 5 years. It treats asthma, exercise‑induced bronchoconstriction and allergic rhinitis in this pediatric population.

GNH India supplies Montelukast 6 Hónap És 5 Év Közötti Gyermekek Számára Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Teva Gyógyszergyár Zrt

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Montelukast is a leukotriene receptor antagonist used in the management of respiratory and allergic conditions.

  • Asthma: improves control of persistent asthma symptoms and reduces the frequency of exacerbations in children.
  • Exercise‑induced bronchoconstriction: prevents narrowing of the airways triggered by physical activity.
  • Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal allergies.

How It Works

  • Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes D4, C4 and E4 from binding. This inhibition reduces bronchoconstriction, vascular permeability, mucus secretion and inflammatory cell recruitment in the airways, thereby improving respiratory function and decreasing allergic inflammation.

Side Effects

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects

  • Headache: mild to moderate pain in the head region.
  • Abdominal pain: discomfort or cramping in the stomach area.
  • Cough: occasional dry or productive cough.
  • Sore throat: irritation or pain in the throat.
  • Fever: transient elevation of body temperature.
  • Nausea: feeling of unease and urge to vomit.

Serious or Rare Side Effects

  • Allergic reactions: rash, angioedema or anaphylaxis requiring immediate medical attention.
  • Neuropsychiatric events: mood changes, depression or suicidal thoughts.
  • Hepatic enzyme elevation: abnormal liver function tests.
  • Stevens‑Johnson syndrome: severe skin blistering and mucosal involvement.
  • Severe rash: widespread erythema or urticaria.
  • Eosinophilic granulomatosis with polyangiitis: rare vasculitic disorder.

Precautions & Warnings

When prescribing Montelukast, clinicians should consider several safety aspects.

  • Dose adjustment: follow prescriber guidance based on the child's age and weight.
  • Monitor for neuropsychiatric symptoms: watch for mood changes, depression or suicidal ideation.
  • Avoid in patients with known hypersensitivity to montelukast or any component of the formulation.
  • Use cautiously in hepatic impairment: consider periodic liver function monitoring.
  • Pregnancy and lactation: safety not established; discuss risks with a healthcare professional.
  • Store at room temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Phenobarbital: may lower montelukast plasma concentrations, reducing therapeutic effect.
  • Rifampin: can induce metabolism and decrease drug effectiveness.
  • Ketoconazole: may increase montelukast levels, raising risk of adverse reactions.

Moderate Interactions (Monitor Closely)

  • Beta‑agonists: additive bronchodilation may enhance respiratory effects.
  • Warfarin: occasional reports of altered INR; monitor coagulation parameters.
  • Epinephrine: potential for enhanced cardiovascular responses; observe patient closely.

Frequently Asked Questions

Montelukast 6 Hónap És 5 Év Közötti Gyermekek Számára Teva is indicated for the treatment of persistent asthma, prevention of exercise‑induced bronchoconstriction, and relief of symptoms associated with allergic rhinitis in children aged six months to five years.

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes D4, C4 and E4 from triggering bronchoconstriction, airway inflammation, mucus production and vascular leakage, thereby improving breathing and reducing allergic symptoms.

The appropriate dose of Montelukast for children aged six months to five years is determined by the prescribing healthcare professional based on the child's weight, age and clinical condition. Patients should follow the prescriber’s instructions exactly.

Safety data for Montelukast in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast is a leukotriene receptor antagonist that targets a different inflammatory pathway than inhaled corticosteroids (ICS). While ICS remain first‑line for most persistent asthma, Montelukast can be used as an add‑on therapy or alternative in patients who cannot tolerate steroids, offering oral administration and specific benefit for exercise‑induced symptoms.

Store Montelukast 6 Hónap És 5 Év Közötti Gyermekek Számára Teva at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, direct sunlight and excessive heat to maintain potency.

Montelukast is taken orally, usually as a tablet that can be swallowed whole or, for younger children, as a chewable or dispersible tablet that is mixed with a small amount of soft food or liquid as directed by the prescriber.

Serious risks include rare allergic reactions such as angioedema or anaphylaxis, neuropsychiatric events like mood changes or suicidal thoughts, and very uncommon severe skin reactions such as Stevens‑Johnson syndrome. Any concerning symptoms should prompt immediate medical evaluation.

Montelukast should be avoided in individuals with a known hypersensitivity to the drug or any of its excipients. It is also contraindicated in patients who have experienced severe allergic reactions to leukotriene‑modifying agents.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Montelukast Sodium

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT